Locking of implanted port for cancer patients
Conditions
Interventions
Exposure group:sealed with normal saline:None
Non-exposure group: Sealed with heparin normal saline (100 U/ml):None
Sponsors
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult cancer patients with newly implanted totally implantable venous access ports (TIVAPs); 2. Patients requiring systemic anti-cancer therapy via intravenous administration; 3. Patients with a treatment duration of =6 months and an expected survival time of >6 months; 4. Patients with a port flushing interval of 3–5 weeks at the end of each treatment cycle; 5. Patients who provide informed consent; 6. Patients with good adherence who are able to understand and cooperate with the study procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity to heparin or a history of heparin-induced thrombocytopenia (HIT); 2. Patients whose newly implanted totally implantable venous access ports (TIVAPs) cannot be used normally due to incision infection, dehiscence, or other related complications; 3. Patients concurrently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of catheter occlusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of catheter patency;Incidence of Catheter-related bloodstream infection (CRBSI);Bleeding at the puncture site;Adverse event; | — |
Countries
China
Contacts
Public ContactYuan Ling
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Outcome results
None listed